Copper complexes as therapeutic agents

Metallomics

Volumn 4, Issue 2, 2012, Pages 127-138

  Duncan, Clare ^a   White, Anthony R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN MODELS; COPPER; DISEASES;

BIOLOGICAL PROCESS; CATALYTIC CHEMISTRY; COFACTORS; COPPER COMPLEXES; CORONARY HEART DISEASE; CU COMPLEXES; CYTOTOXIC; DIAGNOSTIC POTENTIAL; DIVERSE RANGE; INORGANIC COMPLEXES; NEURODEGENERATION; PATHOLOGICAL CONDITIONS; PROTECTIVE EFFECTS; REDUCED-STATE; SKIN DISEASE; THERAPEUTIC AGENTS; TUMOUR CELLS;

COPPER COMPOUNDS;

ACETYLSALICYLATE COPPER; ALPHA HYDROXY CARBOXYLATE; CLIOQUINOL; COPPER COMPLEX; COPPER SULFATE; DP 109; PBT 2; PICOLINIC ACID; POLYGLUTAMIC ACID; PYRIDINE 2 CARBOXAMIDRAZONE; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; SALICYLALDEHYDE; SCHIFF BASE; SUPEROXIDE DISMUTASE; TETRATHIOMOLYBDIC ACID; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTHRITIS; BINDING AFFINITY; BLOOD BRAIN BARRIER; CANCER CELL; CATALYSIS; CELL MEMBRANE; DIABETES MELLITUS; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; ISCHEMIC HEART DISEASE; LEISHMANIASIS; LIPID PEROXIDATION; MALARIA; NEOPLASM; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN DEFECT; SYNAPTOGENESIS; WOUND HEALING;

EID: 84857264431     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/c2mt00174h     Document Type: Review

References (133)

1. E. D. Harris Cellular copper transport and metabolism Annu. Rev. Nutr. 2000 20 291 310
2. T. Wang Z. J. Guo Copper in medicine: Homeostasis, chelation therapy and antitumor drug design Current Medicinal Chemistry 2006 13 525 537
3. J. M. McCord I. Fridovic Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein) J. Biol. Chem. 1969 244 6049
4. B. Halliwell J. M. C. Gutteridge Role of free-radicals and catalytic metal-ions in human-disease-an overview Method Enzymol. 1990 186 1 85 (Pubitemid 20279941)
5. P. A. Sharp Ctr1 and its role in body copper homeostasis Int. J. Biochem. Cell Biol. 2003 35 288 291 (Pubitemid 36084449)
6. H. A. Dierick A. N. Adam J. F. EscaraWilke T. W. Glover Immunocytochemical localization of the Menkes copper transport protein (ATP7A) to the trans-Golgi network Hum. Mol. Genet. 1997 6 409 416 (Pubitemid 27116461)
7. M. J. Petris et al. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: A novel mechanism of regulated trafficking Embo J. 1996 15 6084 6095 (Pubitemid 26397881)
8. J. R. Forbes G. Hsi D. W. Cox Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease J. Biol. Chem. 1999 274 12408 12413
9. H. Roelofsen et al. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion Gastroenterology 2000 119 782 793
10. T. Miyayama K. T. Suzuki Y. Ogra Copper accumulation and compartmentalization in mouse fibroblast lacking metallothionein and copper chaperone, Atox1 Toxicol. Appl. Pharmacol. 2009 237 205 213
11. I. Hamza et al. The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis Proc. Natl. Acad. Sci. U. S. A. 2001 98 6848 6852 (Pubitemid 32538305)
12. R. El Meskini et al. ATP7A (Menkes protein) functions in axonal targeting and synaptogenesis Mol. Cell. Neurosci. 2007 34 409 421 (Pubitemid 46330045)
13. M. L. Schlief T. West A. M. Craig D. M. Holtzman J. D. Gitlin Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity Proc. Natl. Acad. Sci. U. S. A. 2006 103 14919 14924 (Pubitemid 44527829)
14. J. Kardos I. Kovacs F. Hajos M. Kalman M. Simonyi Nerve-endings from rat-brain tissue release copper upon depolarization-a possible role in regulating neuronal excitability Neuroscience Letters 1989 103 139 144 (Pubitemid 19201242)
15. C. Peters et al. Biphasic effects of copper on neurotransmission in rat hippocampal neurons Journal of Neurochemistry 2011 119 78 88
16. X. L. Mao A. D. Schimmer The toxicology of Clioquinol Toxicol. Lett. 2008 182 1 6
17. P. A. Adlard et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A beta Neuron 2008 59 43 55 (Pubitemid 351905863)
18. J. Y. Lee J. E. Friedman I. Angel A. Kozak J. Y. Koh The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice Neurobiology of Aging 2004 25 1315 1321 (Pubitemid 39299169)
19. G. J. Brewer et al. Treatment of Wilson disease with ammonium tetrathiomolybdate-IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease Archives of Neurology 2006 63 521 527
20. R. Schreck B. Meier D. N. Mannel W. Droge P. A. Baeuerle Dithiocarbamates as potent inhibitors of nuclear factor kappa-b activation in intact-cells Journal of Experimental Medicine 1992 175 1181 1194
21. M. Di Vaira et al. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: Structural characterization of its zinc(ii) and copper(ii) complexes Inorganic Chemistry 2004 43 3795 3797
22. P. A. Adlard et al. Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease Plos One 2011 6
23. A. R. White et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity J. Biol. Chem. 2006 281 17670 17680 (Pubitemid 44035565)
24. H. Y. Zhang J. S. Wu F. Y. Peng Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells Anti-Cancer Drugs 2008 19 125 132
25. K. G. Daniel et al. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells Breast Cancer Research 2005 7 R897 R908
26. T. M. Malm et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden Journal of Neuroscience 2007 27 3712 3721 (Pubitemid 46557689)
27. G. Khan S. Merajver Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm Expert Opin. Investig. Drugs 2009 18 541 548
28. I. H. Scheinberg M. E. Jaffe I. Sternlieb The use of trientine in preventing the effects of interrupting penicillamine therapy in wilsons-disease N. Engl. J. Med. 1987 317 209 213 (Pubitemid 17103102)
29. M. Vancailliebertrand H. J. Degenhart I. Luijendijk J. Bouquet M. Sinaasappel Wilsons-disease-assessment of d-penicillamine treatment Arch. Dis. Child. 1985 60 652 655
30. Y. Yu J. Wong D. B. Lovejoy D. S. Kalinowski D. R. Richardson Chelators at the cancer coalface: Desferrioxamine to triapine and beyond Clinical Cancer Research 2006 12 6876 6883 (Pubitemid 44974479)
31. T. W. Hambley Chemistry-Metal-based therapeutics Science 2007 318 1392 1393
32. D. X. West et al. Thiosemicarbazone complexes of copper(ii)-structural and biological studies Coord. Chem. Rev. 1993 123 49 71
33. H. Beraldo D. Gambino The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes Mini-Rev. Med. Chem. 2004 4 31 39 (Pubitemid 38842592)
34. T. S. Lobana R. Sharma G. Bawa S. Khanna Bonding and structure trends of thiosemicarbazone derivatives of metals-An overview Coord. Chem. Rev. 2009 253 977 1055
35. J. L. J. Dearling J. S. Lewis G. E. D. Muller M. J. Welch P. J. Blower Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships JBIC, J. Biol. Inorg. Chem. 2002 7 249 259 (Pubitemid 36056377)
36. P. S. Donnelly et al. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide J. Biol. Chem. 2008 283 4568 4577
37. P. J. Crouch et al. Increasing Cu bioavailability inhibits A beta oligomers and tau phosphorylation Proc. Natl. Acad. Sci. U. S. A. 2009 106 381 386
38. B. M. Paterson P. S. Donnelly Copper complexes of bis(thiosemicarbazones) : from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals Chem. Soc. Rev. 2011 40 3005 3018
39. A. Jemal et al. Global Cancer Statistics Ca-Cancer J. Clin. 2011 61 69 90
40. L. R. Kelland Preclinical perspectives on platinum resistance Drugs 2000 59 1 8 (Pubitemid 30344986)
41. K. B. Garbutcheon-Singh et al. Transition Metal Based Anticancer Drugs Curr. Top. Med. Chem. 2011 11 521 542
42. G. Nalepa M. Rolfe J. W. Harper Drug discovery in the ubiquitin-proteasome system Nat. Rev. Drug Discovery 2006 5 596 613
43. A. D. Schimmer Clioquinol-A Novel Copper-Dependent and Independent Proteasome Inhibitor Curr. Cancer Drug Targets 2011 11 325 331
44. W. Q. Ding S. E. Lind Metal Ionophores-An Emerging Class of Anticancer Drugs IUBMB Life 2009 61 1013 1018
45. D. Chen et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts Cancer Res. 2007 67 1636 1644 (Pubitemid 46383389)
46. X. Mao et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma Leukemia 2009 23 585 590
47. S. M. Zhai et al. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells JBIC, J. Biol. Inorg. Chem. 2010 15 259 269
48. K. G. Daniel P. Gupta R. H. Harbach W. C. Guida Q. P. Dou Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells Biochem. Pharmacol. 2004 67 1139 1151 (Pubitemid 38296793)
49. R. W. Brockman J. R. Thomson M. J. Bell H. E. Skipper Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone Cancer Research 1956 16 167 170
50. R. W. Brockman R. W. Sidwell G. Arnett S. Shaddix Heterocyclic thiosemicarbazones-Correlation between structure, inhibition of ribonucleotide reductase, and inhibition of dna viruses Proc. Soc. Exp. Biol. Med. 1970 133 609
51. C. N. Hancock et al. A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo Free Radical Biol. Med. 2011 50 110 121
52. F. Bisceglie et al. Metal complexes of retinoid derivatives with antiproliferative activity: Synthesis, characterization and DNA interaction studies Eur. J. Med. Chem. 2007 42 627 634 (Pubitemid 46745245)
53. J. S. Lewis D. W. McCarthy T. J. McCarthy Y. Fujibayashi M. J. Welch Evaluation of Cu-64-ATSM in vitro and in vivo in a hypoxic tumor model Journal of Nuclear Medicine 1999 40 177 183 (Pubitemid 29044189)
54. A. L. Vavere J. S. Lewis Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia Dalton Trans. 2007 4893 4902 (Pubitemid 350015414)
55. J. S. Lewis et al. Copper-64-diacetyl-bis(N-4-methylthiosemicarbazone): An agent for radiotherapy Proc. Natl. Acad. Sci. U. S. A. 2001 98 1206
56. J. A. Crim H. G. Petering Antitumor activity of cu(2)kts copper(2) chelate of 3-ethyoxy-2-oxobutyraldehyde bis(thiosemicarbazone) Cancer Research 1967 27 1278
57. L. Bica et al. Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex BioMetals 2011 24 117 133
58. A. Chakraborty P. Kumar K. Ghosh P. Roy Evaluation of a Schiff base copper complex compound as potent anticancer molecule with multiple targets of action Eur. J. Pharmacol. 2010 647 1 12
59. S. Adsule et al. Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells J. Med. Chem. 2006 49 7242 7246 (Pubitemid 44886011)
60. E. W. Ainscough et al. Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships J. Inorg. Biochem. 1999 77 125 133 (Pubitemid 30047061)
61. C. D. Fan J. Zhao B. X. Zhao S. L. Zhang J. Y. Miao Novel Complex of Copper and a Salicylaldehyde Pyrazole Hydrazone Derivative Induces Apoptosis through Up-Regulating Integrin beta 4 in Vascular Endothelial Cells Chem. Res. Toxicol. 2009 22 1517 1525
62. A. Kheirolomoom et al. Copper-Doxorubicin as a Nanoparticle Cargo Retains Efficacy with Minimal Toxicity Mol. Pharmaceutics 2010 7 1948 1958
63. D. Chen Q. Z. C. Cui H. J. Yang Q. P. Dou Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity Cancer Res. 2006 66 10425 10433 (Pubitemid 44799763)
64. M. P. Mattson Pathways towards and away from Alzheimer's disease Nature 2004 430 631 639 (Pubitemid 39061671)
65. C. L. Masters et al. Amyloid plaque core protein in alzheimer-disease and down syndrome Proc. Natl. Acad. Sci. U. S. A. 1985 82 4245 4249 (Pubitemid 15053619)
66. I. Grundkeiqbal et al. Abnormal phosphorylation of the microtubule-associated protein-tau (tau) in alzheimer cytoskeletal pathology Proc. Natl. Acad. Sci. U. S. A. 1986 83 4913 4917
67. M. A. Lovell J. D. Robertson W. J. Teesdale J. L. Campbell W. R. Markesbery Copper, iron and zinc in Alzheimer's disease senile plaques J. Neurol. Sci. 1998 158 47 52 (Pubitemid 28277534)
68. I. Maurer S. Zierz H. J. Moller A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients Neurobiol. Aging 2000 21 455 462 (Pubitemid 30349116)
69. M. Schrag C. Mueller U. Oyoyo M. A. Smith W. M. Kirsch Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion Prog. Neurobiol. 2011 94 296 306
70. R. A. Cherny et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 2001 30 665 676 (Pubitemid 32607332)
71. C. W. Ritchie et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease-A pilot phase 2 clinical trial Arch. Neurol. 2003 60 1685 1691 (Pubitemid 37521621)
72. P. A. Adlard et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A beta Neuron 2008 59 43 55 (Pubitemid 351905863)
73. L. Lannfelt et al. Safety, efficacy, and biomarker findings of PBT2 in targeting A beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 2008 7 779 786
74. N. G. Faux et al. PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses Journal of Alzheimers Disease 2010 20 509 516
75. S. Schaefer F.-G. Pajonk G. Multhaup T. A. Bayer Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels J. Mol. Med. 2007 85 405 413 (Pubitemid 46452257)
76. D. Simon M. Medina J. Avila F. Wandosell Overcoming Cell Death and Tau Phosphorylation Mediated by PI3K-Inhibition: A Cell Assay to Measure Neuroprotection CNS Neurol. Disord.-Drug Targets 2011 10 208 214
77. P. Salcedo-Tello A. Ortiz-Matamoros C. Arias GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration Int. J. Alzheimer's Dis. 2011 2011 189728
78. D. T. Dexter P. Jenner A. H. V. Schapira C. D. Marsden Alterations in levels of iron, ferritin, and other trace-metals in neurodegenerative diseases affecting the basal ganglia Ann. Neurol. 1992 32 S94 S100
79. A. Matusch et al. Cerebral Bioimaging of Cu, Fe, Zn, and Mn in the MPTP Mouse Model of Parkinson's Disease Using Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) J. Am. Soc. Mass Spectrom. 2010 21 161 171
80. M. Alcaraz-Zubeldia P. Rojas C. Boll C. Rios Neuroprotective effect of acute and chronic administration of copper (ii) sulfate against MPP + neurotoxicity in mice Neurochem. Res. 2001 26 59 64 (Pubitemid 32428814)
81. A. Rubio-Osornio et al. Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP(+) in rats Neurochem. Int. 2009 54 447 451
82. D. B. Miller J. F. Reinhard A. J. Daniels J. P. Ocallaghan Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium J. Neurochem. 1991 57 541 549
83. M. Arredondo M. T. Nunez Iron and copper metabolism Mol. Aspects Med. 2005 26 313 327 (Pubitemid 41225355)
84. M.-C. Boll M. Alcaraz-Zubeldia S. Montes C. Rios Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases Neurochem. Res. 2008 33 1717 1723
85. J. H. Fox et al. Mechanisms of Copper Ion Mediated Huntington's Disease Progression PLoS One 2007 2
86. S. L. Hands R. Mason M. U. Sajjad F. Giorgini A. Wyttenbach Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease Biochem. Soc. Trans. 2010 38 552 558
87. T. Nguyen A. Hamby S. M. Massa Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model Proc. Natl. Acad. Sci. U. S. A. 2005 102 11840 11845 (Pubitemid 41170812)
88. S. Krobitsch A. G. Kazantsev Huntington's disease: From molecular basis to therapeutic advances Int. J. Biochem. Cell Biol. 2011 43 20 24
89. I. R. A. Mackenzie R. Rademakers M. Neumann TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia Lancet Neurol. 2010 9 995 1007
90. H. X. Deng et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria Proc. Natl. Acad. Sci. U. S. A. 2006 103 7142 7147
91. J. R. Subramaniam et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading Nat. Neurosci. 2002 5 301 307 (Pubitemid 34279809)
92. M. Neumann et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis Science 2006 314 130 133 (Pubitemid 44547757)
93. T. Ahtoniemi et al. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis Mol. Pharmacol. 2007 71 30 37 (Pubitemid 46020975)
94. O. A. Andreassen A. Dedeoglu P. Klivenyi M. F. Beal A. I. Bush N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis NeuroReport 2000 11 2491 2493 (Pubitemid 30622295)
95. S. Petri et al. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis J. Neurochem. 2007 102 991 1000 (Pubitemid 47057303)
96. E. Tokuda et al. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis Exp. Neurol. 2008 213 122 128
97. J. W. Baynes S. R. Thorpe Role of oxidative stress in diabetic complications-A new perspective on an old paradigm Diabetes 1999 48 1 9 (Pubitemid 29019345)
98. N. Yasumatsu Y. Yoshikawa Y. Adachi H. Sakurai Antidiabetic copper(ii)-picolinate: Impact of the first transition metal in the metallopicolinate complexes Bioorg. Med. Chem. 2007 15 4917 4922 (Pubitemid 46836834)
99. S. Karmaker T. K. Saha H. Sakurai Investigation of a Cu-ii-poly(gamma- glutamic acid) complex in aqueous solution and its insulin-mimetic activity Macromol. Biosci. 2007 7 456 466 (Pubitemid 47237522)
100. S. Sitasawad M. Deshpande M. Katdare S. Tirth P. Parab Beneficial effect of supplementation with copper sulfate on STZ-diabetic mice (IDDM) Diabetes Res. Clin. Pract. 2001 52 77 84 (Pubitemid 32366480)
101. P. R. Scudder et al. Serum copper and related variables in rheumatoid-arthritis Ann. Rheum. Dis. 1978 37 67 70 (Pubitemid 8371827)
102. M. Rister K. Bauermeister U. Gravert E. Gladtke Superoxide-dismutase deficiency in rheumatoid-arthritis Lancet 1978 1 1094 1094
103. J. R. J. Sorenson et al. Copper-complexes-a physiological approach to the treatment of inflammatory diseasesm Inorg. Chim. Acta 1984 91 285 294
104. P. M. Brooks R. O. Day Drug-therapy-nonsteroidal antiinflammatory drugs-differences and similarities N. Engl. J. Med. 1991 324 1716 1725
105. L. A. G. Rodriguez H. Jick Risk of upper gastrointestinal-bleeding and perforation associated with individual nonsteroidal antiinflammatory drugs Lancet 1994 343 769 772 (Pubitemid 24098698)
106. M. A. Agotegaray M. A. Boeris O. V. Quinzani Significant Anti-Inflammatory Properties of a Copper(ii) Fenoprofenate Complex Compared with its Parent Drug. Physical and Chemical Characterization of the Complex J. Braz. Chem. Soc. 2010 21 2294 2301
107. C. T. Dillon et al. Gastrointestinal toxicity, antiinflammatory activity, and superoxide dismutase activity of copper and zinc complexes of the antiinflammatory drug indomethacin Chem. Res. Toxicol. 2003 16 28 37 (Pubitemid 36139408)
108. G. Berthon Is copper pro-inflammatory or antiinflammatory-a reconciling view and a novel-approach for the use of copper in the control of inflammation Agents Actions 1993 39 210 217 (Pubitemid 23349831)
109. J. E. Weder et al. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized Coord. Chem. Rev. 2002 232 95 126
110. A. Omoto et al. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats Arthritis Res. Ther. 2005 7 R1174 R1182
111. R. Ross Mechanisms of disease-Atherosclerosis-An inflammatory disease N. Engl. J. Med. 1999 340 115 126
112. M. Kuzuya et al. Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density-lipoprotein Biochimica Et Biophysica Acta 1992 1123 334 341
113. A. Roland R. A. Patterson D. S. Leake Measurement of copper-binding sites on low density lipoprotein Arterioscler., Thromb., Vasc. Biol. 2001 21 594 602 (Pubitemid 32323394)
114. L. M. Klevay et al. Increased cholesterol in plasma in a young man during experimental copper depletion Metab., Clin. Exp. 1984 33 1112 1118 (Pubitemid 15178785)
115. M. K. Cathcart A. K. McNally D. W. Morel G. M. Chisolm Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cyto-toxin Journal of Immunology 1989 142 1963 1969 (Pubitemid 19081549)
116. D. J. Lamb G. L. Reeves A. Taylor G. A. A. Ferns Dietary copper supplementation reduces atherosclerosis in the cholesterol-fed rabbit Atherosclerosis 1999 146 33 43 (Pubitemid 29371859)
117. D. J. Lamb M. L. Tickner S. M. O. Hourani G. A. A. Ferns Dietary copper supplements modulate aortic superoxide dismutase, nitric oxide and atherosclerosis Int. J. Exp. Pathol. 2005 86 247 255 (Pubitemid 41074390)
118. A. A. Jones R. A. DiSilvestro M. Coleman T. L. Wagner Copper supplementation of adult men: Effects on blood copper enzyme activities and indicators of cardiovascular disease risk Metab., Clin. Exp. 1997 46 1380 1383 (Pubitemid 28053200)
119. T. Radovits et al. Improvement of Aging-Associated Cardiovascular Dysfunction by the Orally Administered Copper(ii)-Aspirinate Complex Rejuvenation Res. 2008 11 945 956
120. P. S. Peres V. A. Terra F. A. Guarnier R. Cecchini A. L. Cecchini Photoaging and chronological aging profile: Understanding oxidation of the skin J. Photochem. Photobiol., B 2011 103 93 97
121. H. Sasaki H. Akamatsu T. Horio Effects of a single exposure to UVB radiation on the activities and protein levels of copper-zinc and manganese superoxide dismutase in cultured human keratinocytes Photochem. Photobiol. 1997 65 707 713 (Pubitemid 27210657)
122. T. Fujimori H. Yasui M. Hiromura H. Sakurai Suppressive effect of orally administered copper(ii)-aspirinate (Cu-2(asp)(4)) complex on the generation of reactive oxygen species in the skin of animals subjected to UVA exposure Exp. Dermatol. 2007 16 746 752 (Pubitemid 47261866)
123. I. Tenaud I. Sainte-Marie O. Jumbou P. Litoux B. Dreno In vitro modulation of keratinocyte wound healing integrins by zinc, copper and manganese Br. J. Dermatol. 1999 140 26 34 (Pubitemid 29074527)
124. A. Simeon et al. Expression and activation of matrix metalloproteinases in wounds: Modulation by the tripeptide-copper complex glycyl-L-histidyl-L- lysine-Cu2+ J. Invest. Dermatol. 1999 112 957 964 (Pubitemid 29277999)
125. F. X. Maquart et al. Stimulation of collagen-synthesis in fibroblast-cultures by the tripeptide-copper complex glycyl-l-histidyl-l-lysine- cu-2+ FEBS Lett. 1988 238 343 346
126. N. Y. Gul A. Topal T. Cangul K. Yanik The effects of topical tripeptide copper complex and helium-neon laser on wound healing in rabbits Veterinary Dermatology 2008 19 7 14
127. I. T. Cangul N. Y. Gul A. Topal R. Yilmaz Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits Vet. Dermatol. 2006 17 417 423 (Pubitemid 44706013)
128. R. D. Maffei J. K. U. Yokoyama-Yasunaka D. C. Miguel S. R. B. Uliana B. P. Esposito Synthesis, characterization and evaluation of antileishmanial activity of copper(ii) with fluorinated alpha-hydroxycarboxylate ligands BioMetals 2009 22 1095 1101
129. A. Portas D. Miguel J. Yokoyama-Yasunaka S. Uliana B. Espsito Increasing the activity of copper(ii) complexes against Leishmania through lipophilicity and pro-oxidant ability Journal of Biological Inorganic Chemistry 1 6
130. D. L. Klayman J. F. Bartosevich T. S. Griffin C. J. Mason J. P. Scovill 2-Acetylpyridine thiosemicarbazones.1. new class of potential anti-malarial agents J. Med. Chem. 1979 22 855 862 (Pubitemid 10234149)
131. N. H. Gokhale et al. Synthesis and characterization of copper(ii) complexes of pyridine-2-carboxamidrazones as potent antimalarial agents Inorg. Chim. Acta 2003 349 23 29
132. N. H. Gokhale K. Shirisha S. B. Padhye et al. Metalloantimalarials: Synthesis, X-ray crystal structure of potent antimalarial copper (ii) complex of arylazo-4-hydroxy-1,2-naphthoquinone Bioorg. Med. Chem. Lett. 2006 16 430 432 (Pubitemid 41680641)
133. S. C. Mohapatra et al. Antimalarial evaluation of copper(ii) nanohybrid solids: inhibition of plasmepsin ii, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum JBIC, J. Biol. Inorg. Chem. 2010 15 373 385